Aprocitentan Drug Asset Due Diligence Report 2026

This Aprocitentan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Aprocitentan can convert its Small molecule drug profile and ETA x ETB biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Aprocitentan (query alias: aprocitentan)
Modality / target	Small molecule drug; ETA x ETB; ETA antagonists, ETB antagonists
Highest global status	Approved
Originator	IDORSIA LTD
Active developers	IDORSIA LTD, Idorsia Pharmaceuticals Deutschland GmbH, Idorsia Pharmaceuticals Ltd.

The MCP disease footprint includes Essential Hypertension, Resistant hypertension, Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07635914	Phase 3	Not yet recruiting	382	Change from baseline in Sitting Systolic Blood Pressure (SiSBP) after 8 weeks of treatment.
NCT05196399	Phase 1	Completed	36	Maximum plasma concentration (Cmax) of aprocitentan
NCT06799884	Phase 1	Completed	19	Maximum plasma concentration (Cmax) of ethinyl estradiol/levonorgestrel

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Aprocitentan for Blood Pressure Reduction in Black Patients

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: 24-hour ambulatory systolic BP = 8.6 mm Hg ; 24-hour ambulatory systolic BP = 4.0 mm Hg

Incidence and Prevalence of Edema and the Effect of Aprocitentan Treatment Strategy in the PRECISION Study

Phase 3; n=838; evaluation: Positive. Reported fields: Incidence of edema(4-week) = 15.9 % ; Incidence of edema(4-week) = 9.1 %

EFFECT OF HIGH DOSE APROCITENTAN IN PATIENTS WITH RESISTANT HYPERTENSION NOT CONTROLLED BY LOW DOSE

Phase 3; n=93; evaluation: Positive. Reported fields: SiSBP control rate = 49.3 % ; SiSBP control rate = 39.8 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Aprocitentan addresses Essential Hypertension, Resistant hypertension, Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-09-06	Idorsia reacquires the world-wide rights to aprocitentan	NDA/BLA	US$230.0M milestones; US$343.8M stated total
2017-06-16	Actelion transfer its drug discovery and early stage clinical pipeline business to Idorsia	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Aprocitentan for the treatment of hypertension”. The milestone feed surfaced a patent-application signal described as “Crystal form of aprocitentan, preparation method therefor and use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO